McKesson Corporation, tracing roots to 1833, is a diversified healthcare services company operating four segments: North American Pharmaceutical (distribution of branded, generic, specialty, biosimilar, and OTC drugs in U.S. and Canada), Oncology & Multispecialty (specialty drug distribution, oncology network support, cell and gene therapy), Prescription Technology Solutions (medication access and affordability technology), and Medical-Surgical Solutions (medical-surgical supplies and pharmaceuticals to non-acute settings). McKesson partners with biopharma companies, pharmacies, care providers, and governments.
Executive Vice President & Chief Financial Officer, McKesson
? – present
Jeni Dominguez
Vice President - Investor Relations, McKesson
? – present
Key Facts from Earnings Calls
Type
Subject
Detail
Quarter
topic_mention
MCK
discussed Cybersecurity
topic_mention
MCK
discussed Regulation
topic_mention
MCK
discussed Healthcare & Bio
topic_mention
MCK
discussed Artificial Intelligence
topic_mention
MCK
discussed Cybersecurity
topic_mention
MCK
discussed Autonomous Vehicles
topic_mention
MCK
discussed Capital Expenditure
topic_mention
MCK
discussed Supply Chain
topic_mention
MCK
discussed Regulation
topic_mention
MCK
discussed Enterprise
topic_mention
MCK
discussed Automotive
topic_mention
MCK
discussed Healthcare & Bio
topic_mention
MCK
discussed AI Compute
topic_mention
MCK
discussed Platform & Ecosystem
metric
MCK free cash flow
reported $9.6 billion
guidance
MCK
guided guidance range for interest expense to $215 million
guidance
MCK
guided outlook includes plans to repurchase approximately $2.5 billion
outlook
MCK
stated We anticipate revenue gro wth of 12% to 16% and operating profit growth of 13% to 17%, reflecting our strong third quarter performance and the confidence that we
outlook
MCK
stated We anticipate revenue to increase 10% to 14% and operating profit to increase 8% to 12%
outlook
MCK
stated we anticipate continued growth of GLP - 1 medication